IGC Pharma (IGC) AI Stock Analysis

• Market Cap: $33.46M
• Dividend Yield: N/A
• Average Volume (3M): 5.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: -5.50%
• EPS Growth: 56.57%
• Country: US
• Employees: 67
• Sector: Healthcare
• Sector Strength: 37
• Industry: Conglomerates
• EPS (TTM): -0.02
• Shares Outstanding: 83,891,590
• 10 Day Avg. Volume: 10,722,420
• 30 Day Avg. Volume: 5,013,418
• PEG Ratio: -0.11
• Price to Book (P/B): 4.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.37
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 5.66
• Enterprise Value/Gross Profit: 43.45
• Enterprise Value/Ebitda: -0.83
• 1Y Price Target: $4.25
• Price Target Upside: 1048.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: $0.50 ▲(35.14%Upside)

IGC Pharma's overall stock score is primarily impacted by weak financial performance and poor valuation metrics. However, technical analysis shows a moderately positive trend, and recent progress in Alzheimer's research presents a potential growth opportunity. The absence of earnings call data limits the analysis of recent management insights.

Positive Factors

Clinical Trials

IGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.

Growth Opportunities

The company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.

Market Potential

The large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.

Negative Factors

Market Risks

The large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

IGC Pharma Business Overview & Revenue Model

Company Description

IGC Pharma (IGC) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of debilitating and life-altering medical conditions. The company's core focus is on leveraging its expertise in cannabinoid-based therapies to address unmet needs in areas such as Alzheimer’s disease, chronic pain, and other neurological disorders. IGC Pharma is dedicated to advancing its pipeline of proprietary research compounds and delivering effective solutions that improve patients' quality of life.

How the Company Makes Money

IGC Pharma generates revenue through the development and commercialization of pharmaceutical products and therapies, particularly those based on cannabinoid compounds. The company's revenue streams include sales of its proprietary products, licensing agreements, and potential collaborations with other pharmaceutical entities. Additionally, IGC may engage in partnerships with research institutions and healthcare organizations to further its research and development efforts, which could result in milestone payments and royalties. These partnerships and collaborations are significant contributors to the company's earnings, enabling it to expand its market presence and enhance its product offerings.

IGC Pharma Financial Statement Overview

Summary

IGC Pharma faces significant financial challenges, characterized by declining revenues, persistent net losses, and negative cash flow. While the company maintains a manageable level of debt, its reliance on external financing and decreasing equity raise concerns about long-term sustainability.

Income Statement

IGC Pharma's revenue has shown fluctuations with a recent decrease. Despite this, gross profit margins have improved, but the company continues to face significant net losses, as reflected in negative net profit and EBIT margins. The decline in revenue and persistent losses highlight challenges in profitability and growth.

Balance Sheet

The company's balance sheet shows moderate leverage with a low debt-to-equity ratio. Equity has declined over the years, indicating reduced financial stability. However, the company maintains a positive equity ratio, suggesting some level of financial resilience despite the decreasing asset base.

Cash Flow

IGC Pharma's cash flow analysis reveals consistent negative free cash flow, indicating challenges in generating cash. The operating cash flow to net income ratio remains negative, reflecting inefficiencies in converting income into cash. Financing activities have been a key source of cash, highlighting reliance on external funding.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	1.27M	1.34M	911.00K	397.00K	898.00K
Gross Profit	619.00K	733.00K	442.00K	194.00K	113.00K
EBITDA	-6.83M	-9.16M	-10.91M	-14.78M	-8.25M
Net Income	-7.12M	-13.00M	-11.51M	-15.02M	-8.81M
Balance Sheet
Total Assets	8.75M	9.90M	17.18M	26.83M	35.87M
Cash, Cash Equivalents and Short-Term Investments	405.00K	1.20M	3.35M	10.46M	14.63M
Total Debt	238.00K	345.00K	481.00K	488.00K	985.00K
Total Liabilities	2.42M	2.58M	2.27M	2.94M	3.06M
Stockholders Equity	6.33M	7.32M	14.91M	23.89M	32.80M
Cash Flow
Free Cash Flow	-5.28M	-5.71M	-7.67M	-8.20M	-12.39M
Operating Cash Flow	-4.79M	-5.20M	-7.05M	-7.46M	-10.80M
Investing Cash Flow	-442.00K	-317.00K	-235.00K	-742.00K	3.39M
Financing Cash Flow	4.45M	3.52M	100.00K	4.14M	14.69M

IGC Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IGC, the sentiment is Positive. The current price of 0.37 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.32, and above the 200-day MA of 0.33, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 55.63 is Neutral, neither overbought nor oversold. The STOCH value of 69.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IGC.

IGC Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCMT	71 Outperform	$193.11M	15.04	42.38%	―	8.53%	-16.64%
SPLP	61 Neutral	$784.79M	3.66	24.14%	―	5.83%	72.33%
FIP	61 Neutral	$770.05M	―	-6.42%	1.34%	5.70%	36.39%
IGC	54 Neutral	$33.46M	―	-104.33%	―	-5.50%	56.57%
TUSK	52 Neutral	$128.50M	―	-55.95%	―	-12.33%	-738.00%
NNBR	47 Neutral	$107.45M	―	-17.87%	―	-7.16%	28.78%
Sector *	46 Neutral	C$201.68M	-3.28	-23.14%	1.87%	20.75%	-0.36%

IGC Pharma Corporate Events

IGC Pharma Highlights Alzheimer’s Research Progress

On June 17, 2025, IGC Pharma released an updated corporate presentation highlighting its clinical study advancements, which will be used in upcoming conferences and meetings with stakeholders. The presentation underscores the company’s progress in Alzheimer’s research, particularly with its IGC-AD1 drug candidate, which has undergone rigorous preclinical and regulatory reviews, showing promising results in reducing Alzheimer’s symptoms and meeting FDA standards.

The most recent analyst rating on (IGC) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on IGC Pharma stock, see the IGC Stock Forecast page.